Title |
A Comprehensive and Observational Myeloproliferative Neoplasms Registry in the Province of Quebec (MPN Registry) |
Protocole ID |
Registre des NMP (CINC424BCA04T) |
ClinicalTrials.gov ID |
|
Cancer Type(s) |
MPN: Vaquez, Essential Thrombocytemia, Myeloid Metaplasia |
Phase |
Other |
Stage |
|
Study Type |
|
Drug |
|
Institution |
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
1755 boul. René-Laennec, Laval, QC, H7M 3L9
|
City |
Laval |
Principal Investigator |
Dr. Danielle Talbot
|
Coordinator |
Solange Tremblay
450-668-1010 poste 23603
|
Status |
Recruiting |
Activation Date |
|
Eligibility Criteria |
All patients who meet the following inclusion criteria may be enrolled in the MPN Registry:
- Have a diagnosis of PV, ET, or MF as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms [7];
- Are 18 years of age or older;
- Are able to give written, informed consent (or have a legal representative who can give written, informed consent when applicable.
|
Exclusion Criteria |
Patients who meet any of the following criteria will be excluded from participation:
- Life expectancy of less than 3 months for a condition not related to MPN;
- Patients suffering of CML.
|
|
|